Traws Pharma’s (TRAW) Neutral Rating Reiterated at HC Wainwright

Traws Pharma (NASDAQ:TRAW)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $1.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 85.19% from the company’s current price.

TRAW has been the subject of a number of other reports. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings downgraded Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. LADENBURG THALM/SH SH lowered Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Finally, Citigroup cut Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Traws Pharma presently has an average rating of “Reduce” and a consensus target price of $1.00.

Traws Pharma Stock Down 5.4%

TRAW opened at $0.54 on Tuesday. Traws Pharma has a twelve month low of $0.43 and a twelve month high of $3.27. The company has a fifty day moving average of $0.71 and a 200-day moving average of $1.35. The stock has a market cap of $8.18 million, a PE ratio of -0.31 and a beta of 1.57.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. Sell-side analysts anticipate that Traws Pharma will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP grew its stake in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the period. Geode Capital Management LLC increased its holdings in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares in the last quarter. State Street Corp acquired a new position in shares of Traws Pharma during the fourth quarter worth approximately $29,000. XTX Topco Ltd raised its position in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after purchasing an additional 31,502 shares during the period. Finally, Seven Fleet Capital Management LP bought a new position in shares of Traws Pharma in the 4th quarter worth $56,000. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.